TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03613493

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit
Description: The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit
Description: The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HPV self-sampling kit
Description: The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV self-sampling kit
Description: The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-targeted Fear Appeal Message
Description: Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Appeal Message
Description: Participants will receive fear appeal messages (only) in a graphically designed kit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview
Description: Participants will be interviewed about experiences using the self-sampling tool (qualitative).
Study: NCT02091700

Intervention type: OTHER
Intervention: Indocyanine Green ICG
Study: NCT02431598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadoxetate disodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadoterate dimeglumine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study: NCT04474483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Methylcellulose) capsule
Description: Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
Study: NCT00424242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Orally beginning at 500 mg/m2 every 3 weeks until disease progression
Study: NCT00023231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: 1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone/prednisone
Description: Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
Study: NCT01195948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B27PD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with no active ingredients to mimic B27PD
Study: NCT00023231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Solution or oral tablet taken daily. Dosage depends on body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral tablet taken once prior to transplant. Dosage dependent on body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bactrim
Description: Oral tablet taken three times per week. Dosage is dependent on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Oral tablet taken daily. Dosage is dependent on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor
Description: Oral tablet taken daily
Study: NCT01835106

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter is used postoperatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment catheter is used postoperatively
Study: NCT02643693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P3L
Description: Ad libitum use for a maximum of three hours.~P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VUSE
Description: Ad libitum use for a maximum of three hours.~VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC
Description: Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
Study: NCT00526617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral capsules
Study: NCT00962286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid.
Study: NCT04487990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated Heparin
Description: Addition of unfractioned heparin to CVVHD system already running under citrate regional anticoagulation.
Study: NCT02774317

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma
Description: FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
Study: NCT00787878

Intervention type: DRUG
Intervention: somatropin
Description: SGA previously treated with Norditropin®

Intervention type: DRUG
Intervention: No treatment given
Description: Untreated SGA

Intervention type: DRUG
Intervention: No treatment given
Description: AGA (Average gestational age)
Study: NCT03261999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Mesylate
Description: Subcutaneous injection of 25mg Leuprolide Mesylate
Study: NCT01021397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHPIV3cp45
Description: 10\^5 TCID50 nasal drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rHPIV3cp45 placebo
Description: 1X-L15 nasal drops
Study: NCT04868669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home, intensive nutrition counseling
Description: * Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~* The messages to be provided through the counseling will be contextualized~* Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~* Counseling sessions will be conducted at the participant's place~* Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~* Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~* Sessions will be tailored according to each participant's need and progress
Study: NCT03835039

Intervention type: DEVICE
Intervention: NIRS
Description: Monitoring cerebral and perirenal perfusion using NIRS
Study: NCT04737525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant placement, bone and soft tissue augmentation on buccal site
Description: 1. Atraumatic extraction~2. Palatinal positioning of tapered implant (BLX) 3.75mm diameter~3. 3-4 mm below vestibular gingival line or 1 mm below bone crest~4. Implant placement~5. Allogenic bone packing of the jumping distance and soft tissue grafting~6. Connective tissue graft (CTG) or porcine-derived membrane~7. Provisional restoration out of occlusion and mandibular movements~8. X-ray

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant placement, bone and soft tissue augmentation on buccal site
Description: 1. Atraumatic extraction~2. Palatinal positioning of tapered implant (BLX) 3.75mm diameter~3. 3-4 mm below vestibular gingival line or 1 mm below bone crest~4. Implant placement~5. Allogenic bone packing of the jumping distance and soft tissue grafting~6. Connective tissue graft (CTG) or porcine-derived membrane~7. Provisional restoration out of occlusion and mandibular movements~8. X-ray
Study: NCT02963480

Intervention type: PROCEDURE
Intervention: Cardiac Surgery

Intervention type: PROCEDURE
Intervention: Cardiac Surgery
Study: NCT01168895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro Inhale (Ciprofloxacin, BAYQ3939)
Description: 32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro Inhale (Ciprofloxacin, BAYQ3939)
Description: 48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
Study: NCT00313235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine and Cyclophosphamide
Description: Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10\^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure.
Study: NCT03457857

Intervention type: OTHER
Group type: OTHER
Intervention: Cleanser
Description: Cosmetic Baby Cleanser/Shampoo

Intervention type: OTHER
Group type: OTHER
Intervention: Cleanser and Lotion
Description: Cosmetic Baby Cleanser/Shampoo and Baby Lotion
Study: NCT02674516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Study: NCT00229671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey 1
Description: During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey 2
Description: If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
Study: NCT02838745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT03194334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegetarian diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegetarian diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 1g creatine/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: pills

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: 0.8g beta-alanine per day
Study: NCT01292408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochloroquine
Description: 800 mg per os once, and then 400 mg per day
Study: NCT00518570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
Study: NCT02251353

Intervention type: PROCEDURE
Intervention: intervention
Description: hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery

Intervention type: DRUG
Intervention: systemic treatment
Description: Systemic therapy
Study: NCT02455128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic listening
Description: Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
Study: NCT00875316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cogane™ (PYM50028)
Description: Orally active neurotrophic factor inducer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cogane™ (PYM50028)
Description: Orally active neurotrophic factor inducer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cogane™ (PYM50028)
Description: Orally active neurotrophic factor inducer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cogane™ (PYM50028)
Description: Orally active neurotrophic factor inducer
Study: NCT01308619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, one capsule daily in the morning
Study: NCT00038766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semapimod
Description: semapipmod 60 mg IV x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semapimod
Description: IV 30 mg x 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo IV
Study: NCT03846934

Intervention type: DEVICE
Intervention: Ultrasonography thoracic
Description: Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
Study: NCT00888875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILMA
Description: Insertion after Induction. Insertion of tracheal tube over device
Study: NCT03609463

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Small change intervention
Description: The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small change intervention
Description: The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-being intervention
Description: The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
Study: NCT04233853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoLiPri intervention
Description: General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual primary care enhanced
Description: Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual primary care enhanced
Description: Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
Study: NCT00089219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFA
Description: vaccine adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFA
Description: vaccine adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFA
Description: vaccine adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: melanoma helper peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: melanoma helper peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: melanoma helper peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: vaccine adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: vaccine adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: vaccine adjuvant
Study: NCT01100424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opti-Free RepleniSH
Description: Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNu MultiPlus
Description: Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A
Description: Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unisol 4
Description: Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
Study: NCT04274205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Brief supportive psychotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Brief supportive psychotherapy
Study: NCT01571388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib
Description: Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib
Description: Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib
Description: Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.